![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ITGBL1 |
Gene summary for ITGBL1 |
![]() |
Gene information | Species | Human | Gene symbol | ITGBL1 | Gene ID | 9358 |
Gene name | integrin subunit beta like 1 | |
Gene Alias | OSCP | |
Cytomap | 13q33.1 | |
Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | B4DN32 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9358 | ITGBL1 | ATC11 | Human | Thyroid | ATC | 8.25e-07 | 6.50e-01 | 0.3386 |
9358 | ITGBL1 | ATC12 | Human | Thyroid | ATC | 4.18e-08 | 2.93e-01 | 0.34 |
9358 | ITGBL1 | ATC2 | Human | Thyroid | ATC | 1.02e-12 | 1.01e+00 | 0.34 |
9358 | ITGBL1 | ATC3 | Human | Thyroid | ATC | 4.28e-09 | 5.96e-01 | 0.338 |
9358 | ITGBL1 | ATC4 | Human | Thyroid | ATC | 4.08e-11 | 2.97e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003158928 | Thyroid | ATC | cell-substrate adhesion | 195/6293 | 363/18723 | 1.58e-15 | 1.17e-13 | 195 |
GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
GO:000722919 | Thyroid | ATC | integrin-mediated signaling pathway | 63/6293 | 107/18723 | 7.09e-08 | 1.24e-06 | 63 |
GO:00336277 | Thyroid | ATC | cell adhesion mediated by integrin | 39/6293 | 72/18723 | 2.59e-04 | 1.66e-03 | 39 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGBL1 | SNV | Missense_Mutation | c.530N>G | p.Phe177Cys | p.F177C | O95965 | protein_coding | deleterious(0.01) | possibly_damaging(0.873) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ITGBL1 | SNV | Missense_Mutation | novel | c.1458A>C | p.Glu486Asp | p.E486D | O95965 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.99) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ITGBL1 | SNV | Missense_Mutation | novel | c.529N>G | p.Phe177Val | p.F177V | O95965 | protein_coding | deleterious(0.02) | benign(0.271) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ITGBL1 | SNV | Missense_Mutation | novel | c.92C>T | p.Ser31Phe | p.S31F | O95965 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.641) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ITGBL1 | SNV | Missense_Mutation | novel | c.644N>C | p.Lys215Thr | p.K215T | O95965 | protein_coding | deleterious(0.02) | probably_damaging(0.989) | TCGA-QS-A5YQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
ITGBL1 | SNV | Missense_Mutation | c.1110C>A | p.Asp370Glu | p.D370E | O95965 | protein_coding | tolerated(0.1) | benign(0.142) | TCGA-DD-A4NV-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ITGBL1 | SNV | Missense_Mutation | c.886N>G | p.Cys296Gly | p.C296G | O95965 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-UB-A7MB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD | |
ITGBL1 | SNV | Missense_Mutation | rs137943907 | c.980N>T | p.Cys327Phe | p.C327F | O95965 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ITGBL1 | SNV | Missense_Mutation | c.1057N>T | p.Asp353Tyr | p.D353Y | O95965 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ITGBL1 | SNV | Missense_Mutation | novel | c.1469N>C | p.Gly490Ala | p.G490A | O95965 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-44-4112-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |